Aurobindo Pharma Q2 profit rises 32% to Rs 1,123.84 crore

Aurobindo Pharma Limited reported consolidated profit after tax of Rs 1,123.84 crore for the quarter ended September 30, 2026, up 32.5% from Rs 848.13 crore a year earlier. Total income from operations rose 23.9% to Rs 10,263.29 crore, meaning profit growth exceeded the increase in operating income.

How did Aurobindo Pharma’s consolidated September-quarter results change?

Aurobindo Pharma’s consolidated profit after tax increased by Rs 275.71 crore year on year to Rs 1,123.84 crore in the quarter ended September 30, 2026. Total income from operations rose by Rs 1,977.59 crore from Rs 8,285.70 crore in the September 2025 quarter to Rs 10,263.29 crore in the latest quarter.

Profit before exceptional items and tax was Rs 1,687.67 crore in the September 2026 quarter, compared with Rs 1,275.92 crore a year earlier. Profit before tax after exceptional items was also Rs 1,687.67 crore, matching the pre-exceptional-items figure in the newspaper extract.

Why did Aurobindo Pharma’s total comprehensive income decline?

Aurobindo Pharma reported total comprehensive income of Rs 1,326.76 crore for the September 2026 quarter, down from Rs 1,389.20 crore in the September 2025 quarter despite higher profit after tax. The results statement defines total comprehensive income as profit after tax plus other comprehensive income after tax.

The amount above profit after tax was Rs 202.92 crore in the September 2026 quarter, compared with Rs 541.07 crore in the year-earlier period. This lower contribution beyond profit after tax accounts for the decline in total comprehensive income, although the extract does not provide a further break-up of other comprehensive income.

Consolidated basic and diluted earnings per share were both Rs 19.57 in the September 2026 quarter, versus Rs 14.61 a year earlier. These earnings-per-share figures were marked not annualised, while paid-up equity share capital was Rs 57.54 crore at September 30, 2026, compared with Rs 58.08 crore in the comparative column.

What do Aurobindo Pharma’s standalone continuing operations show?

Aurobindo Pharma’s standalone profit after tax from continuing operations rose 24.3% to Rs 723.58 crore in the September 2026 quarter from Rs 582.24 crore a year earlier. Standalone total income from continuing operations increased 16.4% to Rs 3,177.33 crore from Rs 2,729.93 crore.

Standalone profit before exceptional items and tax from continuing operations was Rs 970.95 crore, compared with Rs 756.41 crore in the September 2025 quarter. Profit before tax after exceptional items was also Rs 970.95 crore, so the extract does not show a separately reported exceptional-item amount for the latest standalone quarter.

The standalone statement showed no amount for discontinued operations in the September 2026 quarter, while the September 2025 comparative period recorded a Rs 0.87 crore loss after tax from discontinued operations. Standalone total comprehensive income increased to Rs 724.90 crore from Rs 581.34 crore over the same periods.

How did Aurobindo Pharma’s earnings per share compare?

Aurobindo Pharma’s standalone basic earnings per share from continuing operations rose to Rs 12.58 for the September 2026 quarter from Rs 10.02 in the September 2025 quarter. Basic earnings per share for total operations was also Rs 12.58, compared with Rs 10.01 a year earlier.

The Rs 0.01 difference between prior-year earnings per share for continuing and total operations reflected the disclosed discontinued-operations loss. The September 2026 standalone earnings-per-share figures were not annualised, as were the consolidated quarterly figures of Rs 19.57.

For the year ended March 31, 2026, Aurobindo Pharma reported consolidated total income from operations of Rs 33,653.08 crore and profit after tax of Rs 3,502.97 crore. Annual consolidated basic and diluted earnings per share were Rs 60.34 each, compared with Rs 19.57 each for the September 2026 quarter.

What does Aurobindo Pharma’s filing disclose and omit?

Aurobindo Pharma’s results extract establishes that consolidated profit after tax grew faster than operating income in the September 2026 quarter, at 32.5% and 23.9%, respectively. It also records a 24.3% increase in standalone continuing-operations profit after tax and a 33.9% rise in consolidated basic earnings per share.

The November 4, 2026 announcement does not provide segment revenue, product-level performance, management guidance or a breakdown of other comprehensive income. Although the heading refers to the quarter and half year ended September 30, 2026, the published extract presents quarterly comparative figures and March 31, 2026 annual figures.

The company said the full financial results filed under Regulation 33 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015 are available through the BSE, National Stock Exchange and Aurobindo Pharma websites. The filing was signed in Hyderabad on November 4, 2026 by Vice Chairman and Managing Director K. Nithyananda Reddy.

Conclusion

Aurobindo Pharma recorded higher September-quarter income and profit, with consolidated operating income of Rs 10,263.29 crore and profit after tax of Rs 1,123.84 crore. Profit growth outpaced income growth, while total comprehensive income declined because the reported component beyond profit after tax was lower than in the September 2025 quarter.

The next item to watch is the detailed financial-results format referenced in the November 4, 2026 announcement. That fuller filing may resolve matters not detailed in the newspaper extract, including segment performance, half-year figures and the components of other comprehensive income.